Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
eNutriceuticals was a consumer healthcare company that specialized in the development, marketing, and online distribution of nutritional supplements. The company's primary focus was on male enhancement products, most notably its flagship supplement, Vigor-25. In 2008, the company faced severe regulatory action when the FDA discovered that Vigor-25 contained undeclared sildenafil, the active pharmaceutical ingredient in prescription erectile dysfunction medication. This discovery led to a nationwide recall and significant legal challenges that effectively ended the company's primary operations. eNutriceuticals was previously a publicly traded entity on the OTC markets under the ticker symbol ENUT.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on e-nutriceuticals.